Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR).

ABSTRACT: BACKGROUND:Public drug plans are faced with increasingly difficult funding decisions. In Canada, the pan-Canadian Oncology Drug Review (pCODR) makes funding recommendations to the provincial and territorial drug plans responsible for cancer drugs. Assessments of the economic models submitted by pharmaceutical manufacturers are publicly reported. OBJECTIVES:The main objective of this research was to identify recurring methodological issues in economic models submitted to pCODR for funding reviews. The secondary objective was to explore whether there exists any observed relationships between reported methodological issues and funding recommendations made by pCODR's expert review committee. METHODS:Publicly available Economic Guidance Reports from July 2011 (inception) until June 2014 for dru

SUBMITTER: Masucci L 

PROVIDER: S-EPMC5711746 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature